Table 1. Baseline clinical and treatment characteristics.
| Subject | Age at PP symptoms (y) |
Age at letrozole start (y) |
BA/CA | Tanner stage (B/PH) |
Letrozole dose (mg/day) |
Other endocrine |
Other PP treatment |
|---|---|---|---|---|---|---|---|
| 1 | 2 | 4 | 2.0 | - | 2.5 | FD, HT | Medroxyprogesterone ᵵ Leuprolide* |
| 2 | 4.5 | 5.9 | 1.4 | 2/1 | 2.5 | FD | - |
| 3 | 2.5 | 2.4 | 1 | 4/1 | 2.5 | FD | - |
| 4 | 2.8 | 8.3 | 1.4 | 2/2 | 1.9 | FD, PW | - |
| 5 | 3.5 | 6 | 1.2 | 4/3 | 1.5 | FD | - |
| 6 | 2 | 3.8 | 2.0 | - | 1 | FD, HT | Anastrazoleᵵ |
| 7 | 4.2 | 5.8 | 1.4 | 2/2 | 2.5 | FD | - |
| 8 | 1.3 | 4.9 | 1.4 | 4/1 | 1.5 | FD, PW | - |
| 9 | 0.2 | 3.3 | 2.3 | 2/3 | 2.5 | FD, GH, HT, CS |
Cyproteroneᵵ Anastrazoleᵵ Tamoxifen* Leuprolide* |
| 10 | 0.3 | 2 | 2.5 | 4/3 | 1 | FD | - |
| 11 | 4 | 4.7 | 1.8 | 3/1 | 1 | FD, HT | - |
| 12 | 1.7 | 4.6 | 1.5 | 2/1 | 2.5 | FD | - |
| 13 | 3.1 | 6.1 | 1.5 | 3/2 | 1.25 | - | - |
| 14 | 2 | 4.8 | 2.1 | 4/3 | 2.5 | - | Leuprolide* |
| 15 | 0.9 | 3.4 | 1.5 | 4/2 | 1.25 | FD | - |
| 16 | 1.8 | 2.2 | 1.6 | 2/1 | 2.5 | FD | - |
| 17 | 3.1 | 4.3 | 1.7 | 2/1 | 2.5 | FD, GH | - |
| 18 | 3.7 | 7.9 | 1.5 | 2/1 | 2.5 | FD | - |
| 19 | 2.0 | 5.4 | 1.7 | 2/1 | 2.5 | FD | - |
| 20 | 2.9 | 4.3 | 1.9 | 4/1 | 1 | FD | Leuprolide* |
| 21 | 0.5 | 2 | 2.7 | 4/4 | 2.5 | FD, HT, CS | Anastrazoleᵵ |
| 22 | 2.0 | 6 | 1.5 | 2/3 | 2.5 | FD, GH, HT, PW, CS |
Testolactoneᵵ Leuprolide* |
| 23 | 4.8 | 4.8 | 1.2 | 3/1 | 2.5 | FD, HT, PW | - |
| 24 | 2.3 | 4.8 | 1.2 | 3/2 | 2.5 | FD | - |
| 25 | 2.2 | 6.7 | 1.4 | 3/3 | 2.5 | FD, HT | Tamoxifenᵵ |
| 26 | 0.8 | 3.3 | 1.5 | 3/1 | 2.5 | FD, HT | Leuprolideᵵ |
| 27 | 1.5 | 1.5 | 1 | 2/1 | 2.5 | FD, HT | - |
| 28 | 0.1 | 3.9 | 2 | 3/3 | 2.5 | FD, GH, HT, CS |
Tamoxifenᵵ |
PP = precocious puberty, CA = chronologic age, BA = bone age, SD = standard deviation B = breast, PH = pubic hair, y = years, mg = milligrams, FD = fibrous dysplasia, GH = growth hormone excess, HT = hyperthyroidism, PW = phosphate wasting, CS = Cushing syndrome.
ᵵ
Treatment discontinued prior to letrozole.
*
Treatment given concomitantly with letrozole.